Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms.
Marta WlodarczykMichal CiebieraGrażyna NowickaTomasz ŁozińskiMohamed AliAyman Al-HendyPublished in: Nutrients (2024)
The most common malignant gynecologic diseases are cervical, uterine, ovarian, vaginal, and vulvar cancer. Among them, ovarian cancer causes more deaths than any other cancer of the female reproductive system. A great number of women suffer from endometriosis, uterine fibroids (UFs), adenomyosis, dysmenorrhea, and polycystic ovary syndrome (PCOS), which are widespread benign health problems causing troublesome and painful symptoms and significantly impairing the quality of life of affected women, and they are some of the main causes of infertility. In addition to the available surgical and pharmacological options, the effects of supporting standard treatment with naturally occurring compounds, mainly polyphenols, are being studied. Catechins are responsible for the majority of potential health benefits attributed to green tea consumption. Epigallocatechin gallate (EGCG) is considered a non-toxic, natural compound with potential anticancer properties. Antioxidant action is its most common function, but attention is also drawn to its participation in cell division inhibition, apoptosis stimulation and epigenetic regulation. In this narrative review, we describe the role of EGCG consumption in preventing the development of benign reproductive disorders such as UF, endometriosis, and PCOS, as well as malignant gynecologic conditions. We discuss possible epigenetic mechanisms that may be related to the action of EGCG.
Keyphrases
- polycystic ovary syndrome
- insulin resistance
- mental health
- healthcare
- public health
- papillary thyroid
- oxidative stress
- dna methylation
- gene expression
- working memory
- physical activity
- type diabetes
- squamous cell
- depressive symptoms
- health information
- radiation therapy
- single cell
- cell death
- skeletal muscle
- risk assessment
- signaling pathway
- metabolic syndrome
- replacement therapy
- locally advanced
- drug induced
- health promotion
- bone marrow
- neoadjuvant chemotherapy
- childhood cancer
- anti inflammatory